ÂÜÀòÂÒÂ×

Mengqian (Max) Chen, Ph.D., Director of Research. Dr. Chen received graduate and postdoctoral training in prostate cancer and worked as Research Assistant Professor at the University of South Carolina, conducting research on CDK8/19 inhibitor drug discovery and discovering the roles of CDK8/19 in transcriptional reprogramming and prostate cancer. Dr. Chen serves as the Principal Investigator of the Phase II SBIR grant from the National Cancer Institute supporting the development of CDK8/19 inhibitors for prostate cancer therapy.